Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience
G Salles, M Barrett, R Foà, J Maurer, S O'Brien… - Advances in …, 2017 - Springer
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
Follicular lymphoma
A Carbone, S Roulland, A Gloghini, A Younes… - Nature reviews Disease …, 2019 - nature.com
Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
LE Budde, LH Sehn, M Matasar, SJ Schuster… - The Lancet …, 2022 - thelancet.com
Background Mosunetuzumab is a CD20× CD3 T-cell-engaging bispecific monoclonal
antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study …
antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study …
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
F Morschhauser, H Tilly, A Chaidos, P McKay… - The Lancet …, 2020 - thelancet.com
Background Activating mutations of EZH2, an epigenetic regulator, are present in
approximately 20% of patients with follicular lymphoma. We investigated the activity and …
approximately 20% of patients with follicular lymphoma. We investigated the activity and …
[PDF][PDF] Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma
M Dreyling, A Santoro, L Mollica, S Leppä… - Journal of Clinical …, 2017 - researchgate.net
Purpose Phosphatidylinositol 3-kinase (PI3K) signaling is critical for the proliferation and
survival of malignant B cells. Copanlisib, a pan-class I PI3K inhibitor with predominant …
survival of malignant B cells. Copanlisib, a pan-class I PI3K inhibitor with predominant …
[HTML][HTML] Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study
METHODS Patients (> 18 years of age) with previously untreated high–tumor-burden
follicular lymphoma were nonrandomly assigned to receive one of three …
follicular lymphoma were nonrandomly assigned to receive one of three …
Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update
JP Hwang, JJ Feld, SP Hammond, SH Wang… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE This Provisional Clinical Opinion update presents a clinically pragmatic
approach to hepatitis B virus (HBV) screening and management. PROVISIONAL CLINICAL …
approach to hepatitis B virus (HBV) screening and management. PROVISIONAL CLINICAL …
Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression
Whole-genome sequencing of longitudinal tumor pairs representing transformation of
follicular lymphoma to high-grade B cell lymphoma with MYC and BCL2 rearrangements …
follicular lymphoma to high-grade B cell lymphoma with MYC and BCL2 rearrangements …
Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study
M Dreyling, A Santoro, L Mollica… - American journal of …, 2020 - Wiley Online Library
Safety profiles of oral PI3K inhibitors have resulted in US FDA black box warnings regarding
fatal/serious toxicities. The approved intravenous PI3K inhibitor copanlisib has low …
fatal/serious toxicities. The approved intravenous PI3K inhibitor copanlisib has low …
Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020 …
G Kanas, W Ge, RGW Quek, K Keeven… - Leukemia & …, 2022 - Taylor & Francis
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) treatments have been
rapidly evolving for patients treated in later lines of therapy (LoT). Country-specific cancer …
rapidly evolving for patients treated in later lines of therapy (LoT). Country-specific cancer …